David Domzalski - Nov 30, 2024 Form 4 Insider Report for VYNE Therapeutics Inc. (VYNE)

Signature
/s/ Mutya Harsch, Attorney-in-Fact
Stock symbol
VYNE
Transactions as of
Nov 30, 2024
Transactions value $
$8,192
Form type
4
Date filed
12/3/2024, 04:15 PM
Previous filing
Oct 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYNE Common Stock Award $8.19K +3.9K +0.79% $2.10 501K Nov 30, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on June 1, 2024 and ending on November 30, 2024 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on June 3, 2024 (the first trading day of the offering period). The Reporting Person purchased the maximum number of shares permitted by the terms of the ESPP during the calendar year.